Lilly asked the FDA to step in after claiming that testing it’s done suggests copycat versions of Zepbound may carry “unknown ...

Eli Lilly has issued a new warning against buying compounded versions of its drug tirzepatide, claiming to have found potentially dangerous impurities.

Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via WeightWatchers Med+ from $149 per month for a limited time.

A new oral version of the weight loss drug Wegovy has been approved by the FDA, offering a more affordable and accessible ...

After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the ...

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.

GLP-1 medications, such as Ozempic and Wegovy, are injected into the fatty layer beneath the skin to manage blood sugar and aid in weight management. The recommended injection sites include the ...

A previous version of this story had an incorrect title for Brian Dunkin. He is the chief medical officer of endoscopy at Boston Scientific. The story has been corrected. Millions of Americans have ...

Nothing lasts forever, including the pounds shed in a GLP-1 program. A major study published this week finds that people who stop taking weight-loss injections regain all the weight they originally ...

GLP-1 receptor agonists have gained attention as medications to manage type 2 diabetes and obesity. Drugs such as semaglutide and tirzepatide help regulate blood sugar and reduce appetite, which can ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Experts warn the label is ‘more marketing than medical’; urge following evidence on nutritional recommendations for GLP-1 therapy.